Crystal of viral protease inhibitor and use
By controlling the crystal form and salt form of compound 1, the solubility and stability issues in drug development were resolved, providing a crystalline form suitable for industrial production of the coronavirus 3CLpro inhibitor, thus improving the drug's solubility and stability.
Patent Information
- Application Number
- PCT/CN2023/097358
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
In existing technologies, the crystal form and salt form of coronavirus 3CLpro inhibitors have a significant impact on drug properties such as solubility, hygroscopicity, and stability, leading to challenges in drug development and use.
Provide specific crystal forms of compound 1 and its pharmaceutically acceptable salts, such as hydrochloride, fumarate, hippurate, etc., and obtain crystalline forms with excellent solubility, hygroscopicity and stability by controlling crystallization conditions and solvent systems.
The crystalline form of compound 1 exhibits favorable pharmaceutical properties in drug development, is suitable for industrial production, improves drug solubility and stability, and meets the needs of the pharmaceutical industry.
Smart Images

Figure CN2023097358_05122024_PF_FP_ABST
Abstract
Description
Crystallization and use of a viral protease inhibitor Technical Field The present invention relates to the crystallization of an anti-coronavirus protease inhibitor compound and a method for preparing the same, a composition or a pharmaceutical composition comprising the crystallization and use thereof. The present invention also relates to a crystalline salt of the protease inhibitor compound, including hydrochloride, fumarate, hippurate, malonate, methanesulfonate, benzenesulfonate and p-toluenesulfonate, and a method for preparing the salt, a composition or a pharmaceutical composition comprising the above-mentioned salt crystal and use thereof. Technical Background More than 70% of the sequence of the coronavirus genome is used to encode 16 nonstructural proteins (NSPs), named nsp1 to nsp16. These 16 NSPs are translated into two long peptide chains, pp1a and pp1ab, from which single NSPs are produced by proteolysis. The hydrolysis is catalyzed by two proteases among the 16 NSPs, nsp3 and nsp5. Nsp5, 3CLpro, catalyzes the hydrolysis of the peptide bond connecting nsp4 to nsp16. In the catalytic center of 3CLpro, there is a catalytic dyad consisting of His41 and Cys145. The working mechanism and protein sequence of the catalytic domain of 3CLpro are conserved among different coronaviruses. The sequence identity between 3CLpro of SARS-CoV-2 and 3CLpro of SARS-CoV reaches 96%. Inhibiting the protease activity of 3CLpro will block the release of nsp4 to nsp16, which is necessary for the replication of coronavirus. Therefore, 3CLpro is an important target for the development of anti-coronavirus drugs. WO2022150962A1 discloses compounds as inhibitors of coronavirus 3CLpro, including compound 1 described in the present invention, and the entire contents disclosed in the patent document are hereby incorporated into the present application by reference. The disclosed compounds competitively inhibit the binding of 3CLpro substrates to the catalytic pocket of 3CLpro by non-covalent binding, thereby reducing or inhibiting the activity of 3CLpro. Further, the compound can reduce or inhibit the replication of coronavirus. The catalytic pocket-related sequences of coronavirus 3CLpro are highly conserved, and the recognized substrates are also highly conserved. Therefore, this compound can be used as a broad-spectrum inhibitor of coronavirus 3CLpro, and has a therapeutic effect on infections caused by coronavirus viruses including SARS-CoV-2, SARS-CoV, MERS-CoV, etc. Those skilled in the art understand that the crystal form or salt form of a drug and the crystal form of a salt have a significant impact on various drug properties including solubility, hygroscopicity, solid-state stability, bioavailability, etc. Therefore, there is a need for crystal forms and / or salt forms of pharmaceutical compounds that are suitable for drug development, preparation, storage and use. Summary of the invention During the research and development experiments, the inventors surprisingly found that the crystalline compound 1 and certain pharmaceutically acceptable salts thereof exhibit properties particularly suitable for drug development. Therefore, the object of the present invention is to provide a crystalline form of compound 1 or a pharmaceutically acceptable salt thereof suitable for drug development, a pharmaceutical composition comprising the crystalline form, and the medical use of the crystalline form. The name of the compound 1 described in the present invention is: N-((1S, 2R)-2-((4-bromo-2-(methylcarbamoyl)-6-nitrophenyl)amino)cyclohexyl)isoquinoline-4-carboxamide, and its structure is as follows: The present invention can be described from different aspects. The inventions described in these aspects and any embodiments thereof are independent of each other but related to each other, and together constitute the content of the present invention. In a first aspect, the present invention provides a crystalline form of Compound 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a crystal of free form of Compound 1. In some embodiments, the present invention provides a crystal of a pharmaceutically acceptable salt of Compound 1, wherein the salt is selected from the hydrochloride, fumarate, hippurate, malonate, methanesulfonate, benzenesulfonate and p-toluenesulfonate of Compound 1. In a second aspect, the present invention provides a composition comprising the crystalline form described in any embodiment of the first aspect of the present invention, wherein the crystalline form accounts for more than 50% of the mass of the composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%. In a third aspect, the present invention provides a pharmaceutical composition comprising the crystalline form according to any embodiment of the first aspect of the present invention and at least one pharmaceutically acceptable carrier. In a fourth aspect, the present invention provides use of the crystal form described in any embodiment of the first aspect of the present invention in the preparation of a medicament for treating a disease caused by a coronavirus or its symptoms. In a fifth aspect, the present invention provides the crystalline form described in any embodiment of the first aspect of the present invention, the composition described in the second aspect of the present invention, or the pharmaceutical composition described in the third aspect of the present invention, which is used as a medicine. In a sixth aspect, the present invention provides the crystalline form described in any embodiment of the first aspect of the present invention, the composition described in the second aspect of the present invention, or the pharmaceutical composition described in the third aspect of the present invention, which is used to treat diseases or symptoms caused by coronavirus. In a seventh aspect, the present invention provides a method for treating a disease or its symptoms caused by a coronavirus in a subject, comprising the step of administering a therapeutically effective amount of the crystalline form described in any embodiment of the first aspect of the present invention to the patient. Experiments have shown that the crystalline form of Compound 1 or its pharmaceutically acceptable salt provided by the present invention has excellent performance in one or more aspects such as solubility, hygroscopicity and stability, and has good pharmaceutical properties and excellent drug development prospects. The compound 1 or its pharmaceutically acceptable salt provided by the present invention has a high crystal yield and mild crystallization conditions, is suitable for industrial production, and can well meet the needs of the pharmaceutical industry. BRIEF DESCRIPTION OF THE DRAWINGS FIG1A is an XRPD diagram of the free form A of compound 1 FIG1B is a TGA diagram of the free form A of compound 1 FIG1C is a DSC diagram of the free form A of compound 1 FIG. 2A is an XRPD diagram of the free form B of compound 1 FIG2B is a TGA diagram of the free form B of compound 1 FIG2C is a DSC graph of the free form B of compound 1 Figure 3 is an XRPD diagram of the free form C of compound 1 FIG. 4A is an XRPD diagram of the hydrochloride salt form A of compound 1 FIG4B is a TGA diagram of the hydrochloride salt A form of compound 1 FIG4C is a DSC diagram of the hydrochloride salt form A of compound 1 FIG. 5A is an XRPD diagram of the hydrochloride B crystal form of compound 1 FIG5B is a TGA diagram of the hydrochloride B crystal form of compound 1 FIG5C is a DSC diagram of the hydrochloride B crystal form of compound 1 FIG. 6A is an XRPD diagram of the fumarate A crystalline form of compound 1 FIG6B is a TGA / DSC diagram of the fumarate A crystal form of compound 1 FIG. 7A is an XRPD diagram of the hippurate A crystal form of compound 1 FIG. 7B is a TGA diagram of the hippurate A crystal form of compound 1 FIG. 7C is a DSC graph of the hippurate A crystal form of compound 1 FIG8A is an XRPD diagram of the malonate A crystal form of compound 1 FIG8B is a TGA diagram of the malonate A crystal form of compound 1 FIG8C is a DSC graph of the malonate A crystal form of compound 1 FIG. 9A is an XRPD diagram of the mesylate A crystal form of compound 1 FIG9B is a TGA diagram of the mesylate A crystal form of compound 1 FIG9C is a DSC diagram of the mesylate A crystal form of compound 1 FIG. 10A is an XRPD diagram of the benzenesulfonate salt Form A of Compound 1 FIG. 10B is a TGA diagram of the benzenesulfonate salt form A of compound 1 FIG10C is a DSC diagram of the benzenesulfonate salt form A of compound 1 FIG. 11A is an XRPD diagram of the benzenesulfonate salt Form B of Compound 1 FIG. 11B is a TGA diagram of the benzenesulfonate salt of compound 1, Form B FIG11C is a DSC diagram of the benzenesulfonate salt Form B of Compound 1 FIG. 12A is an XRPD diagram of the p-toluenesulfonate salt of compound 1, Form A FIG. 12B is a TGA diagram of the p-toluenesulfonate A crystalline form of compound 1 FIG12C is a DSC diagram of the p-toluenesulfonate A crystalline form of compound 1 FIG. 13A is an XRPD diagram of the p-toluenesulfonate B crystalline form of compound 1 FIG. 13B is a TGA diagram of the p-toluenesulfonate B crystalline form of compound 1 FIG. 13C is a DSC diagram of the p-toluenesulfonate B crystalline form of compound 1 DETAILED DESCRIPTION 1. Definition Unless otherwise indicated, the following terms and phrases used herein have the following meanings. The term "coronavirus" in the present invention refers to a group of related RNA viruses that cause diseases in mammals and birds, such as respiratory infections in humans and birds, ranging from mild to fatal diarrhea in cattle and pigs, and hepatitis and encephalomyelitis in mice. Coronaviruses are enveloped viruses with a positive single-stranded RNA genome and a helical symmetric nucleocapsid. They have characteristic rod-shaped spikes protruding from the surface, which in electron micrographs are reminiscent of the shape of the sun's crown, from which the name of the coronavirus comes. The lethal coronavirus species cover coronaviruses that can cause diseases such as SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and COVID-19 (contact infectious diseases caused by severe acute respiratory syndrome coronavirus 2). The terms "pharmaceutically acceptable" and "pharmaceutically acceptable" in the present invention mean components that are suitable for contact with human and other mammalian tissues without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. "Pharmaceutically acceptable salts" refer to any salts that are non-toxic to the recipient and that can directly or indirectly provide the compounds of the present invention after administration to the recipient. Suitable pharmaceutically acceptable salts are, for example, those disclosed in SM Berge et al., J. Pharmaceutical Sciences, 1977, 66, pp. 1 to 19. For example, pharmaceutically acceptable salts of Compound 1 include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, decanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyrates, alkyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and other salts. The term "subject", "patient" or "recipient" in the present invention refers to an animal susceptible to coronavirus infection, preferably a mammal, and in particular a human. The term "therapeutically effective amount" in the present invention refers to the amount of Compound 1 or its pharmaceutically acceptable salt that produces the desired therapeutic effect (e.g., improvement of a disease and / or disease symptoms caused by a coronavirus, reduction of the severity of a disease and / or disease symptoms caused by a coronavirus, and / or slowing the progression of a disease and / or symptoms caused by a coronavirus). The exact amount of the therapeutically effective amount will depend on the purpose of the treatment and can be determined by those skilled in the art using known techniques. The term "treatment" as used herein includes, but is not limited to, the following: complete or partial relief, cure of a disease caused by a coronavirus, reduction in the risk of a disease and / or symptoms of a disease caused by a coronavirus. The improvement or reduction in severity of any of these symptoms can be evaluated according to methods and techniques known in the art. The term "room temperature" in the present invention means ambient temperature, for example, 10 to 40°C, preferably 15 to 35°C, further 20 to 30°C, for example, about 25°C. The terms "about" and "approximately" herein when used in conjunction with a number such as a percentage include the specified number, and numerical ranges recognized by those of ordinary skill in the art (e.g., ±10%; preferably, ±5%; further preferably, ±2%; most preferably, ±1%). In the present invention, "having characteristic diffraction peaks at approximately the following 2θ angle numbers" and "XRPD spectrum having diffraction peaks at 2θ angle numbers of approximately..." mean that the X-ray powder diffraction spectrum has a diffraction peak within the range of ±0.5° of the indicated 2θ angle number; preferably, within the range of ±0.2°; further preferably, within the range of ±0.1°. In the present invention, "at...℃" means near that temperature, such as an endothermic signal at "65.3℃" means within the range of 65.3℃±1℃; preferably, within the range of ±0.5℃; further preferably, there is an endothermic signal within the range of ±0.2℃. 2. Crystallization of the present invention In some embodiments, the present invention provides a free state crystalline Form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 9.32, 10.39, 13.18, 19.76, 23.84. In some embodiments, the X-ray powder diffraction pattern of the free form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 9.32, 10.39, 13.18, 16.11, 16.78, 19.23, 19.76, 20.30, 20.84, 23.38, and 23.84. In some embodiments, the X-ray powder diffraction pattern of the free form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 6.51, 9.32, 10.39, 11.30, 13.18, 14.67, 16.11, 16.78, 17.98, 19.23, 19.76, 20.30, 20.84, 21.21, 21.95, 23.38, 23.84, 24.64, 25.95, 27.30, 28.08, 30.23, 31.44, 33.93, 36.56, and 38.72. In some embodiments, the XRPD of the free form A of Compound 1 is substantially as shown in Figure 1A. In some embodiments, the TGA results of the free form A of Compound 1 are substantially as shown in Figure 1B. The sample is heated to about 100°C and has a step-wise weight loss of about 4.62%. In some embodiments, the DSC results of the free form A of compound 1 are substantially as shown in Figure 1C. There are two endothermic signals at about 107.8°C and about 129.6°C (peak temperature). In some embodiments, the present invention provides a free-state Form B of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 6.76, 9.07, 13.50, 20.33, and 22.95. In some embodiments, the X-ray powder diffraction pattern of the free form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 6.76, 9.07, 13.50, 13.89, 15.94, 19.10, 20.16, 20.33, 21.03, 21.68, 22.36, 22.95, 24.10, and 27.14. In some embodiments, the X-ray powder diffraction pattern of the free form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 6.76, 8.40, 9.07, 10.79, 13.50, 13.89, 14.61, 15.94, 17.10, 19.10, 20.16, 20.33, 21.03, 21.31, 21.68, 22.00, 22.36, 22.95, 24.10, 24.46, 25.13, 26.53, 27.14, 27.75, 28.46, 29.39, 30.78, 31.98, 34.20, 35.70, and 38.80. In some embodiments, the XRPD of the free form B of Compound 1 is substantially as shown in Figure 2A. In some embodiments, the TGA of the free form B of Compound 1 is substantially as shown in FIG. 2B , and the sample loses about 3.09% of its weight when heated to about 150° C. In some embodiments, the DSC characterization results of the free form B of compound 1 are substantially as shown in FIG. 2C, with 4 endothermic signals at about 50.5°C, about 87.0°C, about 129.5°C, and about 148.4°C (peak temperature). The free form B of compound 1 is heated to about 128°C and cooled to room temperature. The XRPD results show that the form remains unchanged before and after heating, and the sample melts after heating to about 155°C. In some embodiments, the present invention provides a free-state crystalline Form C of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 8.64, 9.23, and 12.99. In some embodiments, the X-ray powder diffraction pattern of the free form C of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.64, 9.23, 12.99, and 20.29. In some embodiments, the XRPD results of the free form C of Compound 1 are substantially as shown in Figure 3. In some embodiments, the present invention provides a hydrochloride salt form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 7.84, 11.11, 18.71, 21.24, and 23.72. In some embodiments, the X-ray powder diffraction pattern of the hydrochloride form A of the compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 7.84, 11.11, 13.54, 18.71, 19.70, 21.24, 22.29, 23.72, and 26.03. In some embodiments, the X-ray powder diffraction pattern of the hydrochloride salt form A of the compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 7.84, 11.11, 12.74, 13.54, 15.07, 15.67, 18.22, 18.71, 19.70, 20.10, 21.24, 21.99, 22.29, 22.81, 23.72, 25.63, 26.03, 26.23, 26.91, 27.42, 28.22, 29.12, 29.94, 30.37, 32.50, 33.68, 34.70, 37.64, and 39.12. In some embodiments, the XRPD results of the hydrochloride salt form A of Compound 1 are substantially as shown in Figure 4A. In some embodiments, the TGA result of the hydrochloride salt form A of compound 1 is substantially as shown in FIG. 4B , and the sample has a weight loss of about 1.35% when heated to about 150° C. In some embodiments, the DSC results of the hydrochloride salt form A of Compound 1 are substantially as shown in FIG. 4C , with one endothermic signal at about 238.6° C. (peak temperature). In some embodiments, the acid-base molar ratio of the hydrochloride salt A form of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a hydrochloride salt form B of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 12.22, 18.37, 22.99, 24.11, and 25.59. In some embodiments, the X-ray powder diffraction pattern of the hydrochloride form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 12.22, 13.72, 18.37, 18.79, 20.28, 21.39, 22.99, 24.11, 25.03, 25.59, 26.92, and 28.27. In some embodiments, the X-ray powder diffraction pattern of the hydrochloride form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 2.22, 13.72, 14.10, 15.04, 17.15, 18.37, 18.79, 19.26, 20.28, 20.93, 21.39, 21.98, 22.99, 24.11, 24.64, 25.03, 25.59, 26.03, 26.45, 26.92, 28.27, 29.83, 30.77, 31.96, 33.05, 35.43, and 37.20. In some embodiments, the XRPD results of the hydrochloride salt Form B of Compound 1 are substantially as shown in Figure 5A. In some embodiments, the TGA result of the hydrochloride Form B of Compound 1 is substantially as shown in FIG. 5B , and the sample has a weight loss of about 1.03% when heated to about 150° C. In some embodiments, the DSC results of the hydrochloride Form B of Compound 1 are substantially as shown in FIG. 5C , with an endothermic signal at about 248.7° C. (peak temperature). In some embodiments, the acid-base molar ratio of the hydrochloride B form of the compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a fumarate salt A crystalline form of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 9.19, 10.92, 18.66, 19.48, and 20.01. In some embodiments, the X-ray powder diffraction pattern of the fumarate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 9.19, 10.92, 11.97, 18.66, 18.90, 19.48, 20.01, 20.21, 23.28, 23.49, and 23.68. In some embodiments, the X-ray powder diffraction pattern of the fumarate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 5.91, 9.19, 10.00, 10.92, 11.97, 12.76, 14.60, 15.94, 17.35, 18.66, 18.90, 19.48, 20.01, 20.21, 20.49, 21.21, 21.94, 23.28, 23.49, 23.68, 24.34, 24.95, 25.70, 26.21, 27.30, 27.98, 28.43, 29.21, 29.72, 30.41, 31.21, 32.19, 33.44, 34.94, and 36.77. In some embodiments, the XRPD results of the fumarate salt Form A of Compound 1 are substantially as shown in FIG. 6A . In some embodiments, the TGA / DSC results of the fumarate salt Form A of Compound 1 are substantially as shown in FIG. 6B , where the sample loses about 1.10% of its weight when heated to about 160° C., and has a sharp endothermic peak at about 187° C. (peak temperature). In some embodiments, the acid-base molar ratio of the fumarate salt form A of Compound 1 is 1:0.5-2, preferably about 1:0.9 or about 1:2. In some embodiments, the present invention provides the hippurate A crystalline form of the compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 4.90, 9.09, 10.73, 19.56, and 21.21. In some embodiments, the X-ray powder diffraction pattern of the hippurate A crystalline form of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 4.90, 9.09, 10.73, 14.64, 19.56, 19.82, 21.01, 21.21, 22.74, 23.96, and 24.84. In some embodiments, the X-ray powder diffraction pattern of the hippurate A crystalline form of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 4.90, 9.09, 10.73, 11.74, 13.06, 13.59, 13.87, 14.64, 14.99, 17.10, 17.34, 18.02, 18.41, 18.74, 19.56, 19.82 、20.08、20.28、21.01、21.21、21.65、22.22、22.74、23.09、23.96、24.50、24.84、25.22、25.44、25.67、26.17、26.57、27.25、28.03、28.81、29.09、29.47、31.46、32.46、34.09、 35.06, 35.77, 36.18, 37.25, 38.90. In some embodiments, the XRPD results of the hippurate salt Form A of Compound 1 are substantially as shown in FIG. 7A . In some embodiments, the TGA result of the hippurate salt Form A of Compound 1 is substantially as shown in FIG. 7B , and the sample loses about 0.72% of its weight when heated to about 150° C. In some embodiments, the DSC results of the hippurate salt form A of Compound 1 are substantially as shown in FIG. 7C , with a sharp endothermic peak at about 151.8° C. (peak temperature). In some embodiments, the acid-base molar ratio of the hippurate A crystal form of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a malonate salt form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 5.36, 8.37, 21.39. In some embodiments, the X-ray powder diffraction pattern of the malonate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 5.36, 8.37, 20.49, 21.39, and 23.75. In some embodiments, the X-ray powder diffraction pattern of the malonate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 5.36, 8.37, 9.90, 11.54, 16.99, 20.49, 21.39, 22.50, 23.75, 25.09, and 27.35. In some embodiments, the XRPD results of the malonate salt Form A of Compound 1 are substantially as shown in FIG. 8A . In some embodiments, the TGA results of the malonate salt Form A of Compound 1 are substantially as shown in FIG. 8B , and the sample loses about 3.26% of its weight when heated to about 100° C., and loses about 10.83% of its weight when further heated to about 180° C. In some embodiments, the DSC results of the malonate salt Form A of Compound 1 are substantially as shown in FIG. 8C , with three endothermic signals at about 53.0° C., about 110.6° C., and about 150.9° C. (peak temperature). In some embodiments, the acid-base molar ratio of the malonate salt A form of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a mesylate salt form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 8.40, 16.95, and 21.30. In some embodiments, the X-ray powder diffraction spectrum of the mesylate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.40, 11.59, 16.95, 21.30, and 25.31. In some embodiments, the XRPD results of the mesylate salt Form A of Compound 1 are substantially as shown in FIG. 9A . In some embodiments, the TGA result of the mesylate salt Form A of Compound 1 is substantially as shown in FIG. 9B , and the sample is heated to about 160° C. and has a step-wise weight loss of about 4.43%. In some embodiments, the DSC results of the mesylate salt Form A of Compound 1 are substantially as shown in FIG. 9C , with two endothermic signals at about 96.7° C. and about 145.5° C. (peak temperature). In some embodiments, the acid-base molar ratio of the mesylate salt A form of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a besylate salt form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 8.62, 19.42, 24.28, 25.62, and 26.00. In some embodiments, the X-ray powder diffraction pattern of the benzenesulfonate salt form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.62, 11.40, 17.24, 19.42, 20.69, 22.28, 23.62, 24.28, 25.62, 26.00, and 27.07. In some embodiments, the XRPD results of the besylate salt Form A of Compound 1 are substantially as shown in FIG. 10A . In some embodiments, the TGA of the benzenesulfonate salt form A of Compound 1 is substantially as shown in FIG. 10B , and the sample loses about 3.34% of its weight when heated to about 120° C., and loses about 5.97% of its weight when further heated to about 180° C. In some embodiments, the DSC results of the besylate salt Form A of Compound 1 are substantially as shown in 10C, with two endothermic signals at about 65.3° C. and about 153.7° C. (peak temperature). In some embodiments, the acid-base molar ratio of the benzenesulfonate salt form A of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a benzenesulfonate salt form B of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 8.89, 9.93, and 22.35. In some embodiments, the X-ray powder diffraction pattern of the benzenesulfonate salt form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.89, 9.93, 17.75, 20.49, and 22.35. In some embodiments, the X-ray powder diffraction pattern of the benzenesulfonate salt form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.89, 9.93, 13.36, 15.35, 17.05, 17.75, 18.49, 20.49, 22.35, 25.58, 26.99, and 28.69. In some embodiments, the XRPD results of Form B of the besylate salt of Compound 1 are substantially as shown in FIG. 11A . In some embodiments, the TGA result of the benzenesulfonate salt Form B of Compound 1 is substantially as shown in FIG. 11B , and the sample loses about 3.67% of its weight when heated to about 180° C. In some embodiments, the DSC results of the benzenesulfonate salt form B of Compound 1 are substantially as shown in 11C, with a sharp endothermic peak at about 194.1° C. (onset temperature). In some embodiments, the acid-base molar ratio of the benzenesulfonate salt form B of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a p-toluenesulfonate salt form A of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 8.38, 19.21, 24.16, 25.75, and 27.09. In some embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.38, 11.42, 16.78, 19.21, 20.55, 21.73, 22.29, 24.16, 25.75, and 27.09. In some embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form A of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 8.38, 11.42, 11.93, 14.59, 16.09, 16.45, 16.78, 18.64, 19.21, 20.55, 21.73, 22.29, 24.16, 25.75, 27.09, and 30.07. In some embodiments, the XRPD results of the p-toluenesulfonate salt Form A of Compound 1 are substantially as shown in FIG. 12A . In some embodiments, the TGA result of the p-toluenesulfonate salt Form A of Compound 1 is substantially as shown in FIG. 12B , and the sample loses about 3.64% of its weight when heated to about 130° C., and loses about 3.17% of its weight when further heated to about 170° C. In some embodiments, the DSC results of the p-toluenesulfonate crystalline form A of Compound 1 are substantially as shown in FIG. 12C , with two endothermic signals at about 122.7° C. and about 150.5° C. (peak temperature). In some embodiments, the acid-base molar ratio of the p-toluenesulfonate salt form A of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. In some embodiments, the present invention provides a p-toluenesulfonate salt Form B of Compound 1, whose X-ray powder diffraction pattern has characteristic diffraction peaks at approximately the following 2θ angles: 7.76, 9.22, 11.99, 18.44, and 21.26. In some embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 5.61, 7.76, 9.22, 11.99, 14.22, 18.44, 21.26, and 23.33. In some embodiments, the X-ray powder diffraction pattern of the p-toluenesulfonate form B of Compound 1 has characteristic diffraction peaks at approximately the following 2θ angles: 5.61, 7.76, 9.22, 10.88, 11.99, 14.22, 15.91, 17.69, 18.44, 21.26, and 23.33. In some embodiments, the XRPD results of the p-toluenesulfonate Form B of Compound 1 are substantially as shown in FIG. 13A . In some embodiments, the TGA result of the p-toluenesulfonate Form B of Compound 1 is substantially as shown in FIG. 13B , and the sample loses about 5.05% of its weight when heated to about 140° C. In some embodiments, the DSC results of the p-toluenesulfonate Form B of Compound 1 are substantially as shown in FIG. 13C , with one endothermic signal at about 154.6° C. (peak temperature). In some embodiments, the acid-base molar ratio of the p-toluenesulfonate salt form A of Compound 1 is 1:0.5-2, preferably 1:0.9-1.1, and more preferably 1:1. 3. Preparation of the Crystal of the Present Invention The crystalline form according to any embodiment of the first aspect of the present invention can be prepared according to the method disclosed in the present application or its obvious alternative method combined with common technical knowledge and routine experimental means in the field. In some embodiments, the free form A of the compound 1 is crystallized by stirring the compound 1 in an aqueous solution of acetonitrile at room temperature and then drying. Preferably, the free form A of Compound 1 is obtained by stirring an amorphous Compound 1 sample in ACN / H2O (1:1, v / v) at room temperature for about 2 days and then vacuum drying overnight. In some embodiments, the free form B of the compound 1 is crystallized by stirring the compound 1 in an aqueous solution of methanol at room temperature and then drying. Preferably, the free form B of compound 1 is obtained by stirring an amorphous sample of compound 1 in MeOH / H2O (1:1, v / v) at room temperature for about 2 days and then vacuum drying overnight. In some embodiments, the free form C of compound 1 is prepared by mixing the compound 1 in methanol. The solvent is evaporated from the aqueous solution at room temperature to obtain crystals. In some embodiments, the hydrochloride salt A form of the compound 1 is prepared by adding the compound 1 to acetone to dissolve it, adding concentrated hydrochloric acid, stirring it magnetically, separating it by suction, and drying it in vacuo at room temperature to obtain crystals. Preferably, magnetic stirring is performed at room temperature for about 2 days and vacuum drying is performed overnight. In some embodiments, the hydrochloride B crystal form of the compound 1 is prepared by adding the compound 1 to acetone to dissolve it, adding concentrated hydrochloric acid, stirring it magnetically, separating it by suction, and drying it in vacuo at room temperature to obtain crystals. Preferably, magnetic stirring is performed at room temperature for about 4 days and vacuum drying is performed overnight. In some embodiments, the fumarate salt form A of Compound 1 is obtained by stirring fumaric acid and Compound 1 in EtOAc at room temperature to precipitate a solid, and then drying in vacuo at room temperature. Preferably, stirring is performed at room temperature for about 2 days, and vacuum drying is performed at room temperature for about 2 days. In some embodiments, the hippurate A crystal form of the compound 1 is prepared by adding the compound 1 to hippuric acid and acetone, stirring magnetically at room temperature, separating the solid, and drying under vacuum at room temperature to obtain crystals. Preferably, magnetic stirring is performed for about 2 days and vacuum drying is performed overnight. In some embodiments, the malonate A crystal form of the compound 1 is prepared by stirring the compound 1 and malonic acid in acetone at room temperature, transferring the mixture to a low temperature stirring state to dissolve, adding the anti-solvent n-heptane to form a gel, and transferring the mixture to a temperature of 50 to 5° C. for circulating suspension stirring and crystallization. Preferably, after stirring at room temperature for 2 days, the mixture is transferred to about 5°C and stirred for about 6 days, and then to -20°C and stirred for about 1 day. In some embodiments, the mesylate salt form A of the compound 1 is prepared by stirring the compound 1 and methanesulfonic acid in acetone at room temperature, and then vacuum drying the solid at room temperature to obtain crystals. Preferably, stirring is performed at room temperature for about 2 days, and vacuum drying is performed at room temperature for about 2 days. In some embodiments, the benzenesulfonate salt form A of the compound 1 is prepared by suspending and stirring the compound and benzenesulfonic acid in an ethanol solution at room temperature, and then drying and crystallizing in vacuo at room temperature. Preferably, the suspension is stirred at room temperature for about 2 days, and vacuum dried at room temperature for about 2 days. In some embodiments, the benzenesulfonate salt form B of the compound 1 is crystallized by suspending and stirring the compound 1 and benzenesulfonic acid in acetone at room temperature. Preferably, the suspension is stirred at room temperature for about 2 days, and vacuum dried at room temperature for about 2 days. In some embodiments, the p-toluenesulfonate salt form A of the compound 1 is prepared by suspending and stirring the compound 1 and p-toluenesulfonic acid in an ethanol solution at room temperature, and then drying and crystallizing under vacuum at room temperature. Preferably, the suspension is stirred at room temperature for about 2 days and vacuum dried for about 2 days. In some embodiments, the p-toluenesulfonate salt Form B of Compound 1 is prepared by suspending and stirring Compound 1 and p-toluenesulfonic acid in ethyl acetate at room temperature, and then drying and crystallizing under vacuum at room temperature. Preferably, the suspension is stirred at room temperature for about 2 days and vacuum dried for about 2 days. 4. Application of the crystal form of the present invention The compound 1 described in the present invention can reduce or inhibit the activity of 3CLpro, and can reduce or inhibit the replication of coronavirus. Therefore, the crystal form of the present invention can be used as a broad-spectrum inhibitor of coronavirus 3CLpro, and is used to treat infections caused by coronavirus viruses including SARS-CoV-2, SARS-CoV, MERS-CoV, etc. For medical applications, the crystal form of the present invention can be administered to patients in need in the form of any standard pharmaceutical composition. The pharmaceutical composition of the present invention comprises a pharmaceutically acceptable carrier, which can be selected from adjuvants and vehicles. The pharmaceutically acceptable carrier used in the present invention can be selected from any and all suitable solvents, diluents, vehicles, dispersing aids, suspension aids, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders and lubricants. Those skilled in the art can select suitable carriers from known pharmaceutically acceptable carriers for the present invention according to the desired specific dosage form. For example, Remington: The Science and Practice of Pharmacy, 21st edition, 2005, edited by DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, J. Swarbrick and JC Boylan, 1988 to 1999, Marcel Dekker, New York disclose various carriers for preparing pharmaceutical compositions and known techniques for preparing them. Non-limiting examples of suitable pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphates, glycine, sorbic acid and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts and electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride and zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, lanolin, sugars (e.g., lactose, glucose and sucrose), starches (e.g., corn starch and potato starch), cellulose and its derivatives (e.g., carboxylic acid). The invention also includes but is not limited to sodium methylcellulose, ethylcellulose and cellulose acetate), tragacanth powder, malt, gelatin, talc, excipients (such as cocoa butter and suppository wax), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol and polyethylene glycol), esters (such as ethyl oleate and ethyl laurate), agar, buffers (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, phosphate buffer, non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), coloring agents, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives and antioxidants. The pharmaceutical composition of the present invention can be administered to a patient in need by any convenient route. For example, the crystalline form of Compound 1, its pharmaceutically acceptable salt or the crystalline form of the salt described in the present invention can be formulated into a corresponding pharmaceutical preparation, so that the preparation can be administered, for example, orally, parenterally, sublingually, topically, rectally, nasally, buccally, vaginally, transdermally, by patch, by pump or via an implanted reservoir. For oral administration, any suitable pharmaceutical carrier commonly used in the preparation of solid preparations can be used, and the crystal formation of the present invention can be formulated into solid preparations, such as syrups, suspensions, emulsions, tablets, capsules and lozenges using formulation techniques known in the art. Examples of these carriers include magnesium stearate, starch, lactose, sucrose, cellulose, etc. Alternatively, any suitable pharmaceutical carrier commonly used in the preparation of liquid preparations can be used, and the crystal formation of the present invention can be formulated into liquid preparations using formulation techniques known in the art. The liquid preparation of the present invention may also contain one or more suspending agents, preservatives, flavoring agents or coloring agents. For administration via parenteral route, any suitable pharmaceutical carrier commonly used in the preparation of parenteral route administration can be used, and the crystal form of the present invention can be formulated into a preparation suitable for parenteral route administration using formulation techniques known in the art, such as sterile injection, lyophilized powder, transdermal patch, aerosol, oral and nasal inhalation and suppository, etc. Parenteral administration routes include intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and local routes. Parenteral administration can be continuous infusion within a selected time. Example In order to better understand the content of the present invention, further description is given below in conjunction with specific embodiments, but the specific implementation methods are not intended to limit the content of the present invention. All solvents used in the following examples were commercially available and were used without further processing unless specifically stated otherwise. The following abbreviations are used in the following examples: v / v indicates volume ratio; ACN means acetonitrile; Acetone means acetone; MeOH means methanol; EtOAc means ethyl acetate; XRPD means X-ray powder diffraction; TGA means thermogravimetric analysis; DSC stands for differential scanning calorimetry; DVS stands for dynamic moisture sorption; UPLC stands for ultra-performance liquid chromatography; SGF indicates simulated gastric fluid; FaSSIF stands for fasting state simulated intestinal fluid; FeSSIF stands for fed state simulated intestinal fluid. Example 1: Preparation of Compound 1 According to WO2022150962A1
[0121] The method disclosed in paragraph
[0128] prepared the free amorphous compound 1 as a yellow solid and used it in the following examples. The specific synthesis steps are shown in the following steps a to d: The reagents and conditions for steps a to d are as further described below: (a) 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), N,N-diisopropylethylamine (DIPEA), CH2Cl2 or dichloromethane (DCM), 0°C, 2h; (b) DIPEA, dimethylformamide (DMF), 80°C, 16h; (c) 3M hydrogen chloride-ethyl acetate (HCl·EA), CH2Cl2, 1h; (d) HATU, DIPEA, DMF, room temperature, 12h. Step a: Synthesis of N-methyl-5-bromo-2-fluoro-3-nitrobenzamide (I-1) At 0 ° C, a solution of 5-bromo-2-fluoro-3-nitrobenzoic acid (0.8 g, 3.80 mmol) in dichloromethane (20 mL) was stirred. Then, HATU (2.0 g, 5.25 mmol), DIPEA (1.88 ml, 11.4 mmol) and methylamine hydrochloride (0.31 g, 4.5 mmol) were added to the reaction. At 0 ° C, the mixture was stirred for 2 hours and the mixture became clear. The mixture was extracted three times with dichloromethane, and the combined organic layer was washed with a saturated saline solution. Then, the organic phase was dried over anhydrous Na2SO4 and concentrated under vacuum. Finally, the mixture was purified by chromatography to obtain compound I-1 (0.8 g, 76% yield) as a yellow solid. Step b: Synthesis of tert-butyl 2-((4-bromo-2-(methylcarbamoyl)-6-nitrophenyl)amino)cyclohexyl)carbamate (I-2) At room temperature, a solution of compound I-1 (0.8g, 2.9mmol) in DMF (15mL) was stirred. Then, tert-butyl ((1S, 2R)-2-aminocyclohexyl) carbamate (0.75g, 3.5mmol) (the corresponding stereoisomer of the reagent can be used to synthesize the stereoisomer of compound I-2) and DIPEA (1.44ml, 8.7mmol) were added to the reaction. The mixture was warmed to 80 ° C and stirred for 16 hours. The mixture was extracted three times with ethyl acetate, and the combined organic layer was washed with a saturated saline solution. Then, the organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo to obtain compound I-2 as a yellow solid without further purification. Yellow solid. Step c: Synthesis of 2-(2-aminocyclohexyl)amino)-5-bromo-N-methyl-3-nitrobenzamide hydrochloride (I-3) At room temperature, a solution of compound I-2 (90 mg, 0.19 mmol) (or the corresponding stereoisomer) in anhydrous dichloromethane (6 mL) is stirred. Then, HCl (4 mL, 3 M in ethyl acetate) is added. At room temperature, the mixture is stirred for 2 hours. The mixture is concentrated under vacuum to obtain compound I-3 as a yellow solid without further purification. Step d: Synthesis of N-((1S,2R)-2-((4-bromo-2-(methylcarbamoyl)-6-nitrophenyl)amino)cyclohexyl)isoquinoline-4-carboxamide A solution of the corresponding isoquinoline-4-carboxylic acid (1 eq.) and HATU (1.5 eq.) in anhydrous DMF (6 mL) was stirred at room temperature. Then, compound I-3 and DIPEA (5.0 eq.) were added. The mixture was stirred overnight at room temperature. The mixture was extracted three times with ethyl acetate, and the combined organic layers were washed with saturated saline solution. The organic phase was then dried over anhydrous Na2SO4 and concentrated in vacuo. Finally, the mixture was purified by chromatography to give the free isoquinoline as a yellow solid. Shaping Compound 1. Example 2: Preparation and characterization of free form A of compound 1 The preparation steps of the free form A of compound 1 are as follows: (1) Weigh 399.9 mg of free amorphous compound 1 into a 20 mL glass bottle and add 10 mL of ACN / H2O (1:1). (2) Magnetic stirring was performed at room temperature for 2 days, and the solid was separated by centrifugation (10000 rpm, 2 min). (3) Vacuum dry at room temperature overnight. The diffraction peak data of the free form A of the compound 1 are shown in Table 1. The XRPD pattern of the free form A of the compound 1 is shown in FIG1A . The TGA diagram of the free form A of the compound 1 is shown in Figure 1B. When the sample is heated to about 100°C, there is a step-wise weight loss of about 4.62%. The DSC graph of the free form A of the compound 1 is shown in Figure 1C. There are two endothermic signals at about 107.8°C and about 129.6°C (peak temperature). Table 1: XRPD diffraction peak data of free form A of compound 1 Example 3: Preparation and characterization of free form B of compound 1 The preparation steps of the free form B of compound 1 are as follows: (1) Weigh 399.9 mg of free amorphous compound 1 into a 20 mL glass bottle and add 10 mL of MeOH / H2O (1:1). (2) Magnetic stirring was performed at room temperature for 2 days, and the solid was separated by centrifugation (10000 rpm, 2 min). (3) Vacuum dry at room temperature overnight. The diffraction peak data of the free form B of the compound 1 are shown in Table 2. The XRPD pattern of the free form B of the compound 1 is shown in FIG2A . The TGA diagram of the free B crystal form of the compound 1 is shown in Figure 2B. The sample loses about 3.09% of its weight when heated to about 150°C. The DSC diagram of the free B crystal form of the compound 1 is shown in Figure 2C. There are 4 endothermic signals at about 50.5°C, about 87.0°C, about 129.5°C and about 148.4°C (peak temperature). The free B crystal form of compound 1 was heated to about 128°C and cooled to room temperature. The XRPD results showed that the crystal form did not change before and after heating, and the sample melted after heating to about 155°C. Table 2: XRPD diffraction peak data of free form B of compound 1 Example 4: Preparation and characterization of free form C of compound 1 The preparation steps of the free form C of compound 1 are as follows: The free form C of compound 1 is obtained by slowly volatilizing a methanol solution of an amorphous sample of compound 1 at room temperature, and after being placed under ambient conditions for 4 days, it transforms into a mixed crystal of the free form B of compound 1 and a small amount of the free form C of compound 1. The diffraction peak data of the free C crystal form of the compound 1 are shown in Table 3. The XRPD pattern of the free form C of the compound 1 is shown in FIG3 . Table 3: XRPD diffraction peak data of free form C of compound 1 Example 5: Preparation and characterization of the hydrochloride salt form A of compound 1 The preparation steps of the hydrochloride A crystal form of compound 1 are as follows: (1) Weigh 400.3 mg of free amorphous compound 1 into a 20 mL glass bottle, add 10 mL of acetone to dissolve it, and then add 65 μL of concentrated hydrochloric acid (38%). (2) The mixture was stirred magnetically at room temperature for 2 days and the solid was separated by filtration. (3) Vacuum drying was performed at room temperature overnight, and a total of 187 mg of sample was collected (yield 43.7%). The diffraction peak data of the hydrochloride salt form A of the compound 1 are shown in Table 4. The XRPD pattern of the hydrochloride salt form A of the compound 1 is shown in FIG4A . The TGA diagram of the hydrochloride A crystal form of the compound 1 is shown in Figure 4B. The sample was heated to about 150°C and had a weight loss of about 1.35%. The DSC graph of the hydrochloride salt form A of the compound 1 is shown in Figure 4C. There is an endothermic signal at about 238.6°C (peak temperature). Table 4: XRPD diffraction peak data of the hydrochloride salt form A of compound 1 Example 6: Preparation and characterization of the hydrochloride B crystal form of compound 1 The preparation steps of the hydrochloride B crystal form of compound 1 are as follows: (1) Weigh 3.0 g of free amorphous compound 1 into a 50 mL glass bottle, add 40 mL of acetone to dissolve it, and then add 512 μL of concentrated hydrochloric acid. (2) The mixture was stirred magnetically at room temperature for 4 days and the solid was separated by filtration. (3) Vacuum drying was performed at room temperature overnight, and a total of 1.72 g of sample was collected (yield 57.3%). The diffraction peak data of the hydrochloride B form of the compound 1 are shown in Table 5. The XRPD pattern of the hydrochloride salt form B of the compound 1 is shown in FIG5A . The TGA chart of the hydrochloride B crystal form of the compound 1 is shown in Figure 5B. The sample was heated to about 150°C and had a weight loss of about 1.03%. The DSC graph of the hydrochloride B crystal form of the compound 1 is shown in Figure 5C. There is an endothermic signal at about 248.7°C (peak temperature). Table 5: XRPD diffraction peak data of the hydrochloride B form of compound 1 Example 7: Preparation and Characterization of Fumarate Form A of Compound 1 The preparation steps of the fumarate A crystalline form of compound 1 are as follows: (1) About 160 mg of free amorphous compound 1 and 18.5 mg of fumaric acid were weighed into a 3 mL glass bottle, and 2 mL of EtOAc was added. (2) Stir magnetically at room temperature for 3 hours and add seed crystals. (3) Magnetic stirring was continued at room temperature for 4 hours, and the solid was separated by centrifugation (10000 rpm, 2 min). (4) Vacuum drying was performed at room temperature overnight, and a total of 140 mg of sample was collected (yield 78.4%). or (1) 399.5 mg of free amorphous compound 1 and 88.0 mg of fumaric acid were weighed into a 20 mL glass bottle, and 10 mL of EtOAc was added. (2) The mixture was stirred magnetically at room temperature for 2 days and the solid was separated by filtration. (3) Vacuum drying was performed at room temperature overnight, and a total of 292 mg of sample was collected (yield 59.9%). The diffraction peak data of the fumarate A crystalline form of the compound 1 are shown in Table 6. The XRPD pattern of the fumarate A crystalline form of the compound 1 is shown in FIG6A . The TGA / DSC graph of the fumarate A crystalline form of the compound 1 is shown in Figure 6B. The sample loses about 1.10% of its weight when heated to about 160°C, and has a sharp endothermic peak at about 187°C (peak temperature). Table 6: XRPD diffraction peak data of fumarate salt A crystal form (826709-47-B3) Example 8: Preparation and characterization of the hippurate salt A crystalline form of compound 1 The preparation steps of the hippurate A crystal form of compound 1 are as follows: (1) Weigh 400.0 mg of free amorphous compound 1 and 136.2 mg of hippuric acid into a 20 mL glass bottle, and add 10 mL of acetone. (2) The mixture was stirred magnetically at room temperature for 2 days and the solid was separated by filtration. (3) Vacuum drying was performed at room temperature overnight, and a total of 303 mg of sample was collected (yield 61.5%). The diffraction peak data of the hippurate A crystal form of the compound 1 are shown in Table 7. The XRPD pattern of the hippurate A crystalline form of the compound 1 is shown in FIG7A . The TGA graph of the hippurate A crystal form of the compound 1 is shown in Figure 7B. The sample loses about 0.72% of its weight when heated to about 150°C. The DSC graph of the hippurate A crystal form of the compound 1 is shown in Figure 7C . There is a sharp endothermic peak at about 151.8° C. (peak temperature). Table 7: XRPD diffraction peak data of the hippurate A crystal form of compound 1 Example 9: Preparation and characterization of the malonate salt of compound 1, form A The preparation steps of the malonate A crystal form of compound 1 are as follows: (1) About 400 mg of the free amorphous compound 1 and an equal mole of malonic acid were stirred in Acetone at room temperature for 2 days. (2) The solution remained clear after being stirred at 5°C for 6 days and at -20°C for 1 day. (3) After adding the anti-solvent n-heptane, it forms a gel. (4) Transfer to 50-5°C temperature and circulate suspension stirring to precipitate solid. The diffraction peak data of the malonate A crystal form of the compound 1 are shown in Table 8. The XRPD pattern of the malonate salt Form A of Compound 1 is shown in FIG8A . The TGA graph of the malonate A crystal form of the compound 1 is shown in Figure 8B. The sample loses about 3.26% of its weight when heated to about 100°C, and loses about 10.83% of its weight when further heated to about 180°C. The DSC graph of the malonate A crystal form of the compound 1 is shown in Figure 8C. There are three endothermic signals at about 53.0°C, about 110.6°C and about 150.9°C (peak temperature). Table 8: XRPD diffraction peak data of malonate A crystal form of compound 1 Example 10: Preparation and characterization of the mesylate salt of compound 1, form A The preparation steps of the mesylate A crystal form of compound 1 are as follows: (1) About 400 mg of the free amorphous compound 1 and an equal mole of methanesulfonic acid were stirred in Acetone at room temperature for 2 days. (2) The solid was dried under vacuum at room temperature for 2 days to obtain mesylate A crystal form. The diffraction peak data of the mesylate A crystal form of Compound 1 are shown in Table 9. The XRPD pattern of the mesylate salt Form A of Compound 1 is shown in FIG9A . The TGA graph of the mesylate A crystal form of Compound 1 is shown in Figure 9B. The sample was heated to about 160°C and had a step-wise weight loss of about 4.43%. The DSC graph of the mesylate A crystal form of the compound 1 is shown in Figure 9C. There are two endothermic signals at about 96.7°C and about 145.5°C (peak temperature). Table 9: XRPD diffraction peak data of mesylate A crystal form of compound 1 Example 11: Preparation and characterization of benzenesulfonate salt form A of compound 1 The preparation steps of the benzenesulfonate A crystal form of compound 1 are as follows: (1) About 400 mg of the free amorphous compound 1 and an equal mole of benzenesulfonic acid were suspended in EtOH / H2O (19:1, v / v) and stirred at room temperature for 2 days. (2) The solid was dried under vacuum at room temperature for 2 days to obtain benzenesulfonate salt Form A. The diffraction peak data of the benzenesulfonate A crystalline form of Compound 1 are shown in Table 10. The XRPD pattern of the benzenesulfonate salt Form A of Compound 1 is shown in FIG10A . The TGA graph of the benzenesulfonate salt form A of the compound 1 is shown in Figure 10B. The sample loses about 3.34% of its weight when heated to about 120°C, and loses about 5.97% of its weight when further heated to about 180°C. The DSC graph of the benzenesulfonate A crystal form of the compound 1 is shown in Figure 10C. There are two endothermic signals at about 65.3°C and about 153.7°C (peak temperature). Table 10: XRPD diffraction peak data of benzenesulfonate salt form A of compound 1 Example 12: Preparation and characterization of benzenesulfonate salt form B of compound 1 The preparation steps of the benzenesulfonate B crystal form of compound 1 are as follows: (1) About 400 mg of the free amorphous compound 1 and an equal mole of benzenesulfonic acid were suspended in Acetone and stirred at room temperature for 2 days. (2) The solid was dried under vacuum at room temperature for 2 days to obtain benzenesulfonate salt Form B. The diffraction peak data of the benzenesulfonate B form of the compound 1 are shown in Table 11. The XRPD pattern of the benzenesulfonate salt Form B of Compound 1 is shown in FIG11A . The TGA chart of the benzenesulfonate B crystal form of the compound 1 is shown in Figure 11B. The sample loses about 3.67% of its weight when heated to about 180°C. The DSC graph of the benzenesulfonate salt form B of the compound 1 is shown in Figure 11C. There is a sharp endothermic peak at about 194.1°C (onset temperature). Table 11: XRPD diffraction peak data of benzenesulfonate salt form B of compound 1 Example 13: Preparation and characterization of the p-toluenesulfonate salt of compound 1, form A The preparation of the p-toluenesulfonate A crystal form of compound 1 is as follows: (1) About 400 mg of the free amorphous compound 1 and an equimolar amount of p-toluenesulfonic acid were suspended in EtOH / H2O (19:1, v / v) and stirred at room temperature for 2 days. (2) The solid was dried under vacuum at room temperature for 2 days. The diffraction peak data of the p-toluenesulfonate A crystalline form of the compound 1 are shown in Table 12. The XRPD pattern of the p-toluenesulfonate salt Form A of Compound 1 is shown in FIG12A . The TGA graph of the p-toluenesulfonate A crystalline form of the compound 1 is shown in Figure 12B. The sample loses about 3.64% of its weight when heated to about 130°C, and loses about 3.17% of its weight when further heated to about 170°C. The DSC graph of the p-toluenesulfonate A crystalline form of the compound 1 is shown in Figure 12C. There are two endothermic signals at about 122.7°C and about 150.5°C (peak temperature). Table 12: XRPD diffraction peak data of the p-toluenesulfonate salt form A of compound 1 Example 14: Preparation and Characterization of Compound 1, p-Toluenesulfonate, Form B The preparation steps of the p-toluenesulfonate B crystal form of compound 1 are as follows: (1) About 400 mg of the free amorphous compound 1 and an equal mole of p-toluenesulfonic acid were suspended in EtOAc and stirred at room temperature for 2 days. (2) The solid was dried under vacuum at room temperature for 2 days. The diffraction peak data of the p-toluenesulfonate B form of the compound 1 are shown in Table 13. The XRPD pattern of the p-toluenesulfonate Form B of the compound 1 is shown in FIG13A . The TGA diagram of the p-toluenesulfonate B crystal form of the compound 1 is shown in FIG13B. The sample loses weight when heated to about 140°C. About 5.05%. The DSC graph of the p-toluenesulfonate B crystalline form of the compound 1 is shown in Figure 13C. There is an endothermic signal at about 154.6°C (peak temperature). Table 13: XRPD diffraction peak data of the p-toluenesulfonate salt Form B of Compound 1 Example 15: Dynamic Solubility Test The 1 / 2 / 4 / 24 hour solubility of the crystalline form obtained in Examples 2-14 in H2O and biological solvents (simulated gastric fluid (SGF), fasting state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF)) was tested, and the experimental results are shown in Table 14. The specific steps of the test are: 1) Weigh about 20-40 mg of the crystalline form of Examples 2-14 into 5-mL glass vials, and add 4 mL of the corresponding medium (H2O, SGF, FaSSIF and FeSSIF). 2) Mix by rotating at 25 rpm on a rotating incubator at 37°C. Samples were taken at 1, 2, 4, and 24 hours. 3) Take about 0.8 mL of the suspension at each sampling point into a centrifuge tube and centrifuge (12000 rpm, 5 min, 37°C). 4) The supernatant was filtered with a PTFE filter membrane (pore size 0.45 μm), and the filtrate was used to test solubility and pH, and the solid was measured by XRPD. Experimental results: Table 14: Dynamic solubility evaluation results S: solubility (mg / mL), in free form. FC: Crystal transition. *: S < 0.1 mg / mL; **: 0.1mg / mL≤S<1mg / mL; ***:1mg / mL≤S. The experimental results show: 1) In H2O, the solubility of the four salt forms is slightly higher than that of the three free samples. 2) In SGF, the solubility of hydrochloride A and B crystal forms was significantly higher than that of fumarate, hippurate and the three free state samples. 3) In FaSSIF, the solubility of fumarate form A is slightly higher than that of hydrochloride form A / B, hippurate form A, free form A / B and free amorphous form. 4) In FeSSIF, there is no significant difference in the solubility of free amorphous form, free crystalline form B, hydrochloride crystalline form A / B, fumarate crystalline form A and hippurate crystalline form A. 5) XRPD results showed that the free amorphous form underwent a crystal transformation after being suspended in FeSSIF for 2 hours. The free crystal forms A / B and the four salt forms did not undergo a crystal transformation in all media. Example 16: Moisture absorption test In accordance with the drug hygroscopicity experimental guidelines of the 2020 edition of the "Chinese Pharmacopoeia", the crystal forms of Examples 2-14 were subjected to DVS testing to determine the hygroscopicity of the crystal forms. The results of the hygroscopicity test are shown in Table 15. Experimental results: Table 15: Moisture absorption test results The DVS results showed that all the tested crystal forms were almost non-hygroscopic, which was a clear advantage over the free amorphous form, and no crystal form transformation occurred in all the crystal forms after the DVS test. Example 17: Solid-state stability test Appropriate amounts of the crystal samples of Examples 2-14 were weighed and placed in an open environment for 7 to 10 days under 25°C / 60%RH and 40°C / 75%RH conditions for stability experiments. The solid samples separated under different conditions were tested for physical stability by XRPD test of crystal form and chemical stability by UPLC test of purity. The solid stability test results are shown in Table 16. The experimental results are shown in the table: Table 16: Solid-state stability results of free amorphous form, free crystalline form and dominant salt form *: The impurity area percentage of RRT = 1.11 is reduced. # : Hydrochloride Form B and Fumarate Form A were placed in the open air for 7 days under two conditions, and the remaining samples were placed in the open air for 2 days under two conditions. Leave for 10 days. The solid-state stability results showed that all the tested crystalline samples did not undergo crystal transformation or purity reduction after being left open for 7 to 10 days at 25°C / 60% RH and 40°C / 75% RH, indicating that they all had good physical and chemical stability under the evaluation conditions. Instruments and methods 1. X-ray powder diffraction (also called "powder X-ray diffraction", X-ray powder diffractometer, XRPD) method The XRPD results were collected on X'Pert3 and Empyrean X-ray powder diffraction analyzers, and the scanning parameters are shown in Table 17. Table 17: XRPD test parameters 2. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) The TGA results were collected on a TA Discovery 5500 thermogravimetric analyzer, and the DSC results were collected on a TA Discovery 2500 differential scanning calorimeter. Table 18 lists the test parameters. Table 18: TGA and DSC test parameters 3. Dynamic moisture sorption (DVS) Dynamic vapor sorption (DVS) curves were collected on the DVS Intrinsic from SMS (Surface Measurement Systems). The relative humidity at 25°C was calibrated using the deliquescent points of LiCl, Mg(NO3)2, and KCl. The DVS test parameters are listed in Table 19. Table 19: DVS test parameters 4. Ultra-Performance Liquid Chromatography (UPLC) In the experiment, the purity, solubility and molar ratio were tested by Waters H-Class UPLC ultra high performance liquid chromatography, and the analysis conditions are shown in Tables 20 and 21. Table 20: UPLC test conditions for purity testing Table 21: ULTRA HPLC test conditions for solubility and molar ratio tests
Claims
1. A crystalline form of a compound of the following formula or a pharmaceutically acceptable salt thereof 2. The crystalline form according to claim 1, wherein the salt is a salt formed by the compound and an acid, and the acid is selected from hydrochloric acid, fumaric acid, hippuric acid, malonic acid, methanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid.
3. The crystal form according to claim 2, characterized in that The compound and the acid form a salt in a molar ratio of 1:0.5-2.
4. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystal form has diffraction peaks at 2θ angles of approximately 9.32, 10.39, 13.18, 19.76, and 23.
84.
5. The crystal form according to claim 1, characterized in that: The XRPD spectrum of the crystal form has diffraction peaks at 2θ angles of approximately 6.76, 9.07, 13.50, 20.33, and 22.
95.
6. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 8.64, 9.23, and 12.
99.
7. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystal form has diffraction peaks at 2θ angles of approximately 7.84, 11.11, 18.71, 21.24, and 23.
72.
8. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 12.22, 18.37, 22.99, 24.11, and 25.
59.
9. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 9.19, 10.92, 18.66, 19.48, and 20.
01.
10. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystal form has diffraction peaks at 2θ angles of approximately 4.90, 9.09, 10.73, 19.56, and 21.
21.
11. The crystal form according to claim 1, characterized in that The XRPD pattern of this crystalline form has diffraction peaks at 2θ angles of approximately 5.36, 8.37, and 21.
39.
12. The crystal form according to claim 1, characterized in that The XRPD pattern of this crystalline form has diffraction peaks at 2θ angles of approximately 8.40, 16.95, and 21.
30.
13. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 8.62, 19.42, 24.28, 25.62, and 26.
00.
14. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 8.89, 9.93, and 22.
35.
15. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystalline form has diffraction peaks at 2θ angles of approximately 8.38, 19.21, 24.16, 25.75, and 27.
09.
16. The crystal form according to claim 1, characterized in that The XRPD spectrum of this crystal form has diffraction peaks at 2θ angles of approximately 7.76, 9.22, 11.99, 18.44, and 21.
26.
17. A composition comprising the crystal form according to any one of claims 1 to 16, wherein the crystal form accounts for more than 50% of the mass of the composition, preferably more than 75%, more preferably more than 90%, and most preferably more than 95%.
18. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 16 and at least one pharmaceutically acceptable carrier.
19. Use of the crystalline form according to any one of claims 1 to 16 in the preparation of a medicament for treating a disease caused by a coronavirus or its symptoms; preferably, the disease is selected from COVID-19, SARS and MERS.
20. The crystalline form according to any one of claims 1 to 16 or the composition according to claim 16 for use as a medicament.
21. The pharmaceutical composition according to claim 18, for treating a disease or symptoms thereof caused by a coronavirus; preferably, the coronavirus is selected from SARS-CoV-2, SARS-CoV and MERS-CoV.
22. A method for treating a disease or symptoms thereof caused by a coronavirus in a subject, comprising administering to the patient a therapeutically effective amount of the crystalline form according to any one of claims 1 to 16; preferably, the disease is selected from COVID-19, SARS and MERS.
Citation Information
Patent Citations
Protease inhibitors, preparation, and uses thereof
WO2022150962A1
Pyridopyrimidine derivatives as protein kinase inhibitors
CN104507942A
Protease inhibitors, and preparation method and use thereof
CN113072497A
Application of PLpro protein inhibitor in medicine for treating or preventing novel coronavirus infection
CN114699419A
Dipeptidyl peptidase inhibitors
US7732446B1
